Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $19.7650 (-2.8%) ($19.6850 - $21.0200) on Tue. Jan. 26, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.23% (three month average) | RSI | 40 | Latest Price | $19.7650(-2.8%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -2% a day on average for past five trading days. | Weekly Trend | FOLD declines -5.8% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(53%) IWO(49%) XBI(48%) IWM(46%) IWC(43%) | Factors Impacting FOLD price | FOLD will decline at least -1.615% in a week (0% probabilities). VIXM(-28%) VXX(-13%) UUP(-11%) UNG(-6%) USO(-1%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.615% (StdDev 3.23%) | Hourly BBV | -2.1 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $11.05(-44.09%) | Inflection Point | Yes | Resistance Level | $22.15 | 5 Day Moving Average | $20.5(-3.59%) | 10 Day Moving Average | $21.45(-7.86%) | 20 Day Moving Average | $22.15(-10.77%) | To recent high | -20.7% | To recent low | 11.5% | Market Cap | $5.104b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |